Other equities analysts have also recently issued research reports about the stock. HC Wainwright set a $35.00 price target on shares of Stemline Therapeutics and gave the company a buy rating in a research report on Thursday, June 20th. Roth Capital reaffirmed a buy rating on shares of Stemline Therapeutics in a research report on Thursday, May 23rd. ValuEngine raised shares of Stemline Therapeutics from a hold rating to a buy rating in a research report on Thursday, March 21st. Piper Jaffray Companies set a $23.00 price objective on shares of Stemline Therapeutics and gave the stock a buy rating in a research report on Monday, March 18th. Finally, Zacks Investment Research raised shares of Stemline Therapeutics from a sell rating to a hold rating in a research report on Tuesday, March 5th. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock has an average rating of Buy and a consensus price target of $25.20.
Stemline Therapeutics stock opened at $14.74 on Friday. Stemline Therapeutics has a fifty-two week low of $7.82 and a fifty-two week high of $18.00. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.07 and a quick ratio of 5.03. The firm has a 50 day moving average of $14.63. The firm has a market cap of $695.46 million, a P/E ratio of -4.93 and a beta of 1.25.
Stemline Therapeutics (NASDAQ:STML) last posted its earnings results on Friday, May 10th. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by ($0.06). The company had revenue of $5.05 million for the quarter, compared to analysts’ expectations of $2.61 million. As a group, research analysts predict that Stemline Therapeutics will post -2.14 earnings per share for the current year.
In related news, COO Kenneth Hoberman sold 25,817 shares of the business’s stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of $14.27, for a total value of $368,408.59. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 13.10% of the stock is owned by insiders.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Stemline Therapeutics in the first quarter valued at $36,000. Great West Life Assurance Co. Can acquired a new position in Stemline Therapeutics in the fourth quarter valued at $47,000. Legal & General Group Plc increased its stake in Stemline Therapeutics by 27.1% in the fourth quarter. Legal & General Group Plc now owns 5,249 shares of the biopharmaceutical company’s stock valued at $50,000 after purchasing an additional 1,120 shares during the period. BNP Paribas Arbitrage SA acquired a new position in Stemline Therapeutics in the first quarter valued at $102,000. Finally, Metropolitan Life Insurance Co. NY increased its stake in Stemline Therapeutics by 327.0% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 8,523 shares of the biopharmaceutical company’s stock valued at $81,000 after purchasing an additional 6,527 shares during the period. 77.66% of the stock is owned by hedge funds and other institutional investors.
Stemline Therapeutics Company Profile
Stemline Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older.
See Also: What does RSI mean?
Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.